At Hypera Pharma, we consider it essential that our conduct in carrying out our business is marked by integrity, compliance and transparency.
We do not tolerate or encourage unethical practices or violations of the current legislation or our Code of Ethical Conduct, of our policies and internal rules, including corruption, fraud, and other irregularities provided in the Law 12.846/13, among others.
Click here to learn more about our Ethical & Compliance Program, our Code of Ethical Conduct and our Anti-Corruption Policy. If you have any questions, please contact compliance@hypera.com.br.
Annual Reports
Relatório Anual
Sustainability Strategy
In 2024, we renewed our materiality assessment, which identifies the key themes guiding the Group’s initiatives and supports our long-term strategy. With the support of a specialized external consultancy, the study was previously discussed in a meeting of the Governance and Sustainability Committee on January 23, 2025, and submitted for discussion and approval at a Board of Directors meeting held on January 28, 2025.
Integrated perspective
|
Access to healthcare |
|
| Attraction, retention, and talent development |
|
| Business ethics |
|
| Product safety and quality |
|
| Commitment to innovation |
|
| Waste management |
|
| Climate change |
|
| Natural resources management |
|
MAIN ESG HIGHLIGHTS
- Hypera Pharma complies with the Novo Mercado regulation, a highly differentiated corporate governance standard in Brazil;
- Hypera Pharma has a Statutory Audit Committee that follows the criteria of the Brazilian Securities and Exchange Commission (CVM);
- Hypera Pharma has a Legal and Compliance Executive Board reporting directly to the CEO and the Statutory Audit Committee;
- Hypera Pharma maintains a unified mandate for Board members of up to two years, with the possibility of re-election;
- In 2024, 44% of the Board of Directors is independent, according to Novo Mercado criteria;
- In 2024, 100% of the Board of Directors is independent, according to SAM (DJSI) criteria;
- In 2024, 33% of the Board of Directors is composed of women;
- In 2024, 33% of the Board of Directors is composed of foreign members;
- In 2024, 67% of the Board of Directors has relevant experience in GICS level 1 industry;
- 100% attendance of the Board of Directors in meetings in 2024;
- Hypera Pharma is a signatory of the UN Global Compact and annually reaffirms its commitment and reports progress on human rights, labor, environment, and anti-corruption initiatives;
- Since 2018, it has published its emissions in the Public Emissions Registry;
- Since 2020, it has published its annual reports guided by the Global Reporting Initiative (GRI);
- Since 2020, it has conducted a materiality assessment to guide its ESG strategy and reviews it periodically;
- Since 2021, it has published its annual reports based on the global Sustainability Accounting Standards Board (SASB) framework;
- Since 2024, the Company has had a Governance and Sustainability Committee;
- Hypera Pharma is part of the FTSE4Good Index Series of the London Stock Exchange;
- Hypera Pharma is included in the Corporate Sustainability Index (ISE) of B3;
- To ensure minimal socio-environmental impact, Hypera Pharma’s plants are located in controlled, industrial areas;
- Hypera Pharma monitors, among many other actions, the handling of products and generation of hazardous waste, water consumption, effluent generation, and greenhouse gas (GHG) emissions;
- Hypera Pharma disposes of waste properly in accordance with regulations of the relevant environmental authorities;
- Hypera Pharma follows the recommendations of the TCFD (Task Force on Climate-related Financial Disclosures) and reports its emissions to the CDP (formerly Carbon Disclosure Project).